Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · IEX Real-Time Price · USD
4.260
-0.130 (-2.96%)
At close: Jul 19, 2024, 4:00 PM
4.250
-0.010 (-0.23%)
Pre-market: Jul 22, 2024, 6:13 AM EDT
Monte Rosa Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for GLUE stock have an average target of 12.25, with a low estimate of 11 and a high estimate of 16. The average target predicts an increase of 187.56% from the current stock price of 4.26.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for GLUE stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Reiterates $16 | Buy | Reiterates | $16 | +275.59% | Jun 28, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +158.22% | May 22, 2024 |
| Wedbush | Wedbush | Buy Initiates $11 | Buy | Initiates | $11 | +158.22% | Feb 15, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $31 → $11 | Buy | Maintains | $31 → $11 | +158.22% | Oct 19, 2023 |
| Credit Suisse | Credit Suisse | Hold Reiterates $11 | Hold | Reiterates | $11 | +158.22% | Aug 11, 2023 |
Financial Forecast
Revenue This Year
1.48M
Revenue Next Year
3.70M
from 1.48M
Increased by 149.73%
EPS This Year
-2.14
from -2.63
EPS Next Year
-1.97
from -2.14
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 4.3M | 18.7M | 81.9M | 368.6M | 671.0M |
| Avg | 1.5M | 3.7M | 18.6M | 131.3M | 276.9M |
| Low | n/a | n/a | n/a | n/a | 19.6M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 1,158.8% | 2,112.9% | 1,880.5% | 411.1% |
| Avg | - | 149.7% | 402.8% | 605.5% | 110.9% |
| Low | - | - | - | - | -85.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -1.70 | -1.38 | -1.40 | 1.43 | 4.70 |
| Avg | -2.14 | -1.97 | -2.09 | -0.94 | 0.26 |
| Low | -2.35 | -2.31 | -3.62 | -2.40 | -2.45 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.